PAX5 and acute lymphoblastic leukemia: In addition, concomitant CDKN2A/B and PAX5 alterations were found in 4/8 patients (50%), all of them diagnosed with B-ALL, and a pathogenic somatic variant in CDKN2A was identified in one patient diagnosed with B-ALL.